* 中国海西新药2637.HK周三早盘劲升14.5%，创7月10日以来新高。
* 该公司此前公告称，候选药物分子HX9428用于治疗新生血管性年龄相关性黄斑变性（nAMD）的美国临床试验申请已获美国食品药品监督管理局（FDA）批准，涵盖一项II期临床试验方案，旨在评估HX9428不同口服剂量在美国nAMD患者中的有效性及安全性。
同时，公司已于中国启动HX9428治疗nAMD的第二项II期临床研究，头对头对比评估HX9428与临床标准疗法药物阿柏西普的有效性及安全性。
nAMD是一种严重威胁老年人视力的慢性眼底疾病，其主要病理特征为脉络膜新生血管异常形成并导致视网膜下液体渗出、出血及视力下降。
* 海西新药今年迄今劲涨45.4%，同期恒生指数.HSI上扬1.1%。
* 恒生生物科技指数.HSBIO盘中一度升2.1%。（完）
更多股市简讯请点选CN-CMN-HOT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.